Sildenafil in COVID-19

Launched by UNIVERSIDAD NACIONAL ANDRES BELLO · Jul 25, 2020

Keywords

ClinConnect Summary

Perfusion anomalies, namely hypoperfusion of healthy lung and vasoplegia with hyperperfusion of diseased lung areas, have been recently described amongst patients with COVID19. In this triple-blind pilot randomised trial, adult patients with high clinical suspicion of SARS-CoV2 infection and perfusion defects in a substraction computed tomography angiography will be randomised in a 1:1 ratio to receive sildenafil or placebo. Informed consent will be obtained from every included participant. Patients requiring mechanical ventilation at baseline will be excluded, as will those who present a c...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult participant with high clinical suspicion of a SARS-CoV2 infection.
• • Hypoperfusion of healthy lung areas in a substraction computed tomography angiography within 24 hours of admission to the hospital.
• Exclusion Criteria:
• • Requirement of therapy with nitrates of nitrites
• • Arterial hypotension at presentation
• • Recent diagnosis of coronary artery disease (\<6 months)
• • Acute heart failure at presentation
• • Recent stroke (\< 6 months)
• • Chronic respiratory failure with CO2 retention
• • Known hypersensitivity to sildenafil
• • Advanced liver disease (Child-Pugh class B or higher)
• • Users of cytochrome P450 3A4 inhibitors (Erythromycin, Ketoconazole, Itraconazole, Saquinavir)
• • Pulmonary hypertension
• • Chronic users of phosphodiesterase 5 inhibitors
• • Requirement of invasive mechanical ventilation at baseline
• • Decision to limit therapeutic efforts at baseline
• • Pregnancy or lactation
• • History of retinitis pigmentosa
• • Known obstruction to left-ventricular outflow tract
• • Unwillingness to participate in the trial